-
-
关键词:
- 假性甲状旁腺功能减退症Ⅰa型 /
- GNAS基因 /
- 急性脑卒中
-
表 1 患者实验室检查
日期 PTH(pg/mL) 血钙(mmol/L) 血磷(mmol/L) 甲状腺功能 其他 2016年5月31日 336.9↑ 1.61↓ 1.61↑ 正常 ACTH、皮质醇昼夜节律正常;TRAb、Anti-TPO阴性;生长激素、性激素、三大常规正常、肝肾功能、血糖、血脂、感染四项、碱性磷酸酶、25羟基维生素D正常 2018年3月9日(门诊随访) 436.3↑ 2.08↓ 1.34 TSH:6.34 mIU/L↑ 未测 2019年9月15日 417.2↑ 1.89↓ 1.53↑ TSH:5.89 mIU/L↑ 25羟基维生素D:59.6nmol/L↓;三大常规、肝肾功能、血糖、糖化血红蛋白、血脂、肌钙蛋白I、心肌酶谱基本正常 注:PTH正常参考范围为12.4~76.8 pg/mL;TSH参考范围为0.38~5.34 mIU/L;25羟基维生素D正常参考范围为75~250 nmol/L。 表 2 PHP患者临床特点
编码 诊断年龄 性别 症状及相关疾病 体征 1~30[1] 1.1~27.8岁,平均年龄8.94岁 男/女: 15/15 手足抽搐4/29;癫痫发作6/29;白内障4/29;齿异常8/30 矮身材10/28;超重及超重8/25;标准体重17/25;圆脸21/25;短指(趾)畸形29/30;异位钙化灶14/25 31~52[2] 8个月~16岁,平均年龄4.4岁 男/女: 9/13 表达第1个有意义单词的平均年龄: 1.67岁(范围为1.00~3.00岁,正常人标准为1.00岁);第1次独立行走平均年龄: 1.34岁(范围为0.90~2.24岁,正常人标准为1.12岁) 矮身材4/22;超重及肥胖17/22;标准体重5/22;圆脸19/22;短指(趾)畸形18/22;异位钙化灶11/22 53[3] 64岁 女 抽搐、癫痫发作、认知损害、双侧髋关节置换术、高血压、血脂异常、30岁闭经 身高145cm;超重;圆脸、鼻扩大、短指(趾)畸形;皮下及颅内钙化灶 54[4] 11个月 男 智力发育迟缓 身高72.6 cm;超重;圆脸、手指短而粗;皮下异位钙化(皮肤活检提示) 55[5] 11岁 女 智力与同龄儿童无明显区别 身高120cm;体质量37kg;圆脸、短颈、盾状胸、指短畸形(双手十指明显短于同龄儿)、下肢呈“X”形、步履蹒跚,双侧Trousseau征阳性 56 30岁 男 乏力、举步困难 矮身材;标准体重;圆脸;短指(趾)畸形;异位钙化灶 表 3 PHP患者相关实验室检测数据(例)
编码 PTH 血钙 血磷 甲状腺功能 生长激素缺乏 性腺激素 ACTH、皮质醇 降钙素 基因突变类型 1~30 升高30/30 降低15/28;正常13/28 升高23/27;正常4/27 亚临床甲减17/28;甲减10/28;正常1/28 缺乏3/13;不缺乏10/13 正常16/16 - - 移码突变9/29;错义突变7/29;无义突变6/29;剪接位点突变3/29;反转突变1/29;重复突变1/29;缺失突变1/29;1例未发现突变 31~52 升高21/22,正常1例 降低11/22;正常11/22 - 亚临床甲减3/22;甲减12/22;正常7/22 - - - - 未记录 53 升高 降低 升高 甲减 正常 正常 正常 升高 移码突变 54 正常;2岁时升高 正常 正常 正常;2岁时亚临床甲减 正常 - - - 移码突变 55 升高 降低 升高 甲减 - 正常 - - 错义突变 56 升高 降低 升高 亚临床甲减 正常 正常 正常 - 移码突变 注:“-”代表未测。 -
[1] FERNÁNDEZ-REBOLLO E, LECUMBERRI B, GAZTAMBIDE S, et al. Endocrine profile and phenotype-(epi)genotype correlation in Spanish patients with pseudohypoparathyroidism[J]. J Clin Endocrinol Metab, 2013, 98(5): E996-1006. doi: 10.1210/jc.2012-4164 [2] MIYAKAWA Y, TAKASAWA K, MATSUBARA Y, et al. Language delay and developmental catch-up would be a clinical feature of pseudohypoparathyroidism type 1A during childhood[J]. Endocr J, 2019, 66(3): 215-221. doi: 10.1507/endocrj.EJ18-0326 [3] DEL MONTE P, CUTTICA C M, MARUGO A, et al. Unrecognized pseudohypoparathyroidism type 1A as a cause of hypocalcemia and seizures in a 64-year-old woman[J]. Case Rep Endocrinol, 2019, 2019: 8456239. http://downloads.hindawi.com/journals/crie/2019/8456239.pdf [4] KODO K, MAEDA H, MORIMOTO H, et al. A case of pseudohypoparathyroidism type Ia with a novel frameshift mutation in the GNAS gene: Early diagnosis of osteoma cutis by skin biopsy[J]. Clin Pediatr Endocrinol, 2019, 28(1): 15-18. doi: 10.1297/cpe.28.15 [5] 沈珉, 柳林, 刘阳, 等. GNAS基因新生突变致假性甲状旁腺功能减退症Ⅰa型1例[J]. 临床儿科杂志, 2017, 35(8): 601-604. doi: 10.3969/j.issn.1000-3606.2017.08.010 [6] UNDERBJERG L, SIKJAER T, MOSEKILDE L, et al. Pseudohypoparathyroidism-epidemiology, mortality and risk of complications[J]. Clin Endocrinol(Oxf), 2016, 84(6): 904-911. doi: 10.1111/cen.12948 [7] DAVID K, STINKENS K, DECALLONNE B. Pseudohypoparathyroidism: A missed window of treatment opportunity?[J]. Acta Neurol Belg, 2020. DOI: 10.1007/s13760-019-01268-3. [8] LINGLART A, LEVINE M A, JVPPNER H. Pseudohypoparathyroidism[J]. Endocrinol Metab Clin North Am, 2018, 47(4): 865-888. doi: 10.1016/j.ecl.2018.07.011 [9] HEJLESEN J, UNDERBJERG L, GJØRUP H, et al. Dental anomalies and orthodontic characteristics in patients with pseudohypoparathyroidism[J]. BMC Oral Health, 2019, 20(1): 2. http://www.ncbi.nlm.nih.gov/pubmed/31892351 [10] HAN S R, LEE Y A, SHIN C H, et al. Clinical and molecular characteristics of GNAS inactivation disorders observed in 18 korean patients[J]. Exp Clin Endocrinol Diabetes, 2021, 129(2): 118-125. doi: 10.1055/a-1001-3575 [11] LEMOS M C, THAKKER R V. GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders[J]. Hum Mutat, 2015, 36(1): 11-19. doi: 10.1002/humu.22696 [12] MANTOVANI G, BASTEPE M, MONK D, et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: First international Consensus Statement[J]. Nat Rev Endocrinol, 2018, 14(8): 476-500. doi: 10.1038/s41574-018-0042-0 [13] SINGLA M, GARG G, GUPTA A. Pseudohypoparathyroidism type 1a[J]. QJM, 2018, 111(5): 331-333. doi: 10.1093/qjmed/hcy038 [14] DE SANCTIS L, GIACHERO F, MANTOVANI G, et al. Genetic and epigenetic alterations in the GNAS locus and clinical consequences in Pseudohypoparathyroidism: Italian common healthcare pathways adoption[J]. Ital J Pediatr, 2016, 42(1): 101. doi: 10.1186/s13052-016-0310-3 [15] FASIH A. Pseudohypoparathyroidism and cardiomyopathy: A case report with a new perspective on the cardiovascular-endocrine axis with respect to calcium homeostasis[J]. Eur J Case Rep Intern Med, 2019, 6(2): 000993. [16] GERMAIN-LEE E L. Management of pseudohypoparathyroidism[J]. Curr Opin Pediatr, 2019, 31(4): 537-549. doi: 10.1097/MOP.0000000000000783